TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06115421

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roxadustat
Description: hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs)
Study: NCT05035641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AND017
Description: Orally, 3 times per week in Period 1 and randomize to TIW or QW group at the same dose in Period 2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally, 3 times per week
Study: NCT04916782

Intervention type: OTHER
Intervention: Quality of life Questionnaire
Description: Quality of life questionnaire
Study: NCT04478292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Thiosulfate Injection
Description: Weight ≥ 10 kg: 20 g/m2/dose STS or Weight 5-10 kg: 15 g/m2/dose STS or Weight \< 5 kg: 10 g/m2/dose STS will be administered by IV over 2 hours beginning 6 hours after the completion of each cisplatin infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Thiosulfate Injection
Description: Weight ≥ 10 kg: 20 g/m2/dose STS or Weight 5-10 kg: 15 g/m2/dose STS or Weight \< 5 kg: 10 g/m2/dose STS will be administered by IV over 2 hours beginning 6 hours after the completion of each cisplatin infusion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary surgery resection
Description: Resection of the primary tumor up-front

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mono CDDP-Group A2
Description: Cisplatin 100 mg/m2/dose Day 1 . All non-WDF patients (A2) will receive 2 cycles of mono cisplatin (100 mg/m2/dose) chemotherapy. Each cycle lasts 3 weeks (21 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin, 5-Fluorouracil, Vincristine, Doxorubicin-Group C
Description: All the patients in Group C (2 arms) will receive 6 cycles chemotherapy in total. Cisplatin 100 mg/m2/dose Day 1; 5-Fluorouracil 600 mg/m2/dose Day 1; Vincristine 1.5 mg/m2/dose Day 1,8 and 15; Doxorubicin 30 mg/m2/dose Day 1 and 2; (Dexrazoxane : 300 mg/m2/dose Day 1 and 2, where is available)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Tumors are deemed unresectable at diagnosis.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Tumors are deemed unresectable at diagnosis.
Study: NCT05103644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80mg
Description: patients received statin experimental group
Study: NCT05103644

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: patients received placebo control group
Study: NCT06109116

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self myofascial release+ Conventional PT
Description: The participant will be asked to sit on a chair and feet resting on the ground. A tennis ball is used on the sole of each foot behind the metatarsal heads to the heel Conventional PT including Hot pack,Knee to chest exercise, Bridging exercise, Straight leg raise exercise, Ankle pumping exercise, Superman position exercise concentrating on the medial arch for 2 minutes in sitting position,with as much pressure as they could, pushing into discomfort but not pain Frequency: 3 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 35 mins Type: Self myofascial release to improve hamstring flexibility

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional PT
Description: Hot pack,Knee to chest exercise, Bridging exercise, Straight leg raise exercise, Ankle pumping exercise, Superman position exercise .~Frequency: 3 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 30 mins
Study: NCT06329401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP01
Description: Oral inhalation solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP01
Description: Oral inhalation solution

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral inhalation solution
Study: NCT05574166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-8356
Description: SP-8356 demonstrates anti-atherosclerotic and anti-ischaemic activity as a novel CD147 inhibitor.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for SP-8356 powder
Study: NCT05386823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HF1K16
Description: HF1K16 for Injection doses will be calculated based on subject weight measured at admission, and diluted in sterile saline (0.9% sodium chloride). Doses will be administered using an IV infusion pump over a period of approximately 60 minutes at 2.5 mL/min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HF1K16
Description: HF1K16 for Injection doses will be calculated based on subject weight measured at admission, and diluted in sterile saline (0.9% sodium chloride). Doses will be administered using an IV infusion pump over a period of approximately 60 minutes at 2.5 mL/min.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be sterile saline (0.9% sodium chloride) which will be administered using an IV infusion pump over a period of approximately 60 minutes at 2.5 mL/min.
Study: NCT06142422

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: stimulation device
Description: The procedure under study is the use of a stimulation device to perform treatment on the precuneus to treat resistant schizophrenia in patients exposed to childhood trauma.~The target is the left precuneus, which is defined by neuronavigation.
Study: NCT04302389

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: myWW App, Virtual Workshops, and Private Facebook Group
Description: The 6-month intervention includes the use of WW's mobile app, weekly virtual workshops, and a private online community. Participants are given a personalized food plan based on expert healthy eating guidelines and the latest nutritional science, an activity plan designed to promote regular physical activity and techniques to help shift members towards a helpful mindset for lasting change all within the WW app. Participants will attend weekly virtual workshops led by an expert WW Coach. The coach will help with goal setting, overcoming setbacks, and follow-up on progress toward goals each week. Participants will be encouraged to participate in a private Facebook group that gives participants an opportunity to receive motivational support from each other. Participants can post about their journey through photos, videos, and comments.
Study: NCT05424900

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rethink game
Description: REThink is a online therapeutic game developed by David and collaborators (2018), proved to be an efficient intervention for the reduction of emotional symptoms in children and adolescents.
Study: NCT05260970

Intervention type: PROCEDURE
Intervention: Rectus muscle reapproximation at cesarean section
Description: Rectus muscle reapproximation: Continuous Suturing of rectus muscles with 2.0 Vicryl (Ethicon) at Cesarean section.
Study: NCT06074003

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Seated Rest (Non-exercise control)
Description: Sitting for 30 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Seated Rest (Non-exercise control)
Description: Sitting for 30 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise
Description: Performing a single session of high-intensity interval exercise on a cycle ergometer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise
Description: Performing a single session of high-intensity interval exercise on a cycle ergometer
Study: NCT05086939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous MSCs
Description: Intra-articular injection 40 million/4 ml.
Study: NCT06142422

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stimulation device
Description: The procedure under study is the use of a stimulation device to perform treatment on the precuneus to treat resistant schizophrenia in patients exposed to childhood trauma.~The target is the left precuneus, which is defined by neuronavigation.
Study: NCT05086939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogenic MSCs
Description: Intra-articular injection 40 million/4 ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid
Description: Intra-articular injection 60mg / 3 ml .
Study: NCT06505629

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the online Paired Emotion Reading Intervention (PERI)
Description: In the PERI, all children will receive three books about emotion knowledge. The paired reading groups will read and discuss these books over the next six weeks. Before starting the reading sessions, the paired groups will meet online via video to get to know each other and set reading goals. During the reading process, participants will check in daily with their reading progress. From the second week to the fifth week, participants will engage in weekly online discussions about the reading content. These discussions, led by the urban children, will follow a semi-structured discussion guide. The discussions aim to deepen the children's understanding of the book content and facilitate the application of emotion-related knowledge and emotion regulation strategies in their daily lives. The discussion sessions will be recorded and uploaded for regular review by the researchers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: the online Paired General Reading Intervention (PGRI)
Description: Apart from the differences in the reading materials and discussion topics, all other aspects are identical to the PERI group. In the online PGRI, children will read three books of their choice, and discussions will center around general reading experiences and feelings.
Study: NCT06334692

Intervention type: DIAGNOSTIC_TEST
Intervention: In-house ELISA, and ELISA kits from DBA Italy (Abbexa).
Description: Nunc MaxiSorp ELISA plates will be coated with recombinant extracellular domain of human nephrin. Patient serum samples will be added in appropriate dilution. Plates will be then incubated with biotin-conjugated anti human IgG antibody followed by incubation with horseradish peroxidase (HRP)-avidin conjugate. Then tetramethylbenzidine substrate will be added, and absorbance read at 450 nm.

Intervention type: DIAGNOSTIC_TEST
Intervention: In-house ELISA, and ELISA kits from DBA Italy (Abbexa).
Description: Nunc MaxiSorp ELISA plates will be coated with recombinant extracellular domain of human nephrin. Patient serum samples will be added in appropriate dilution. Plates will be then incubated with biotin-conjugated anti human IgG antibody followed by incubation with horseradish peroxidase (HRP)-avidin conjugate. Then tetramethylbenzidine substrate will be added, and absorbance read at 450 nm.
Study: NCT05644665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT05155059

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagStim
Description: Bursts of three at 50Hz with an inter burst interval of 200 ms will be given for 190 seconds and this session will be repeated 3 times with 20 minutes between each session in one day. The set of 3 sessions will be repeated 5 times in 5 consecutive days.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: Sham TMS stimulation using a sham coil
Study: NCT05983159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Oral alpha-specific PI3-kinase inhibitor
Study: NCT04986540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1906；Placebo
Description: Drug: SHR-1906 IV, single dose~Drug: Placebo IV, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1906；Placebo
Description: Drug: SHR-1906 IV, single dose~Drug: Placebo IV, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1906；Placebo
Description: Drug: SHR-1906 IV, single dose~Drug: Placebo IV, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1906；Placebo
Description: Drug: SHR-1906 IV, single dose~Drug: Placebo IV, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1906；Placebo
Description: Drug: SHR-1906 IV, single dose~Drug: Placebo IV, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1906；Placebo
Description: Drug: SHR-1906 IV, single dose~Drug: Placebo IV, single dose
Study: NCT04996875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bezuclastinib
Description: Bezuclastinib is administered as tablets to be taken orally, continuously in 28-day cycles.
Study: NCT06339047

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Projector Kaleidoscope
Description: Children in the projector kaleidoscope group will be watched for approximately 5 minutes before induction in the operating room.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cartoon
Description: Children in the cartoon group will be asked which cartoon they want to watch from the cartoon pool and will be shown the cartoon they want. The cartoon duration is approximately 5 minutes.
Study: NCT06582147

Intervention type: OTHER
Group type: OTHER
Intervention: Implementation of social determinants of health screening and referral
Description: WE CARE is a relatively simple, low-intensity intervention that has two key components: (1) screening individuals using the WE CARE SDOH Screener for unmet social needs, and (2) providing individuals who have unmet social needs with SDOH Community Resource sheets
Study: NCT06424912

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vivifi's Surgical Procedure
Description: Subjects undergo Vivifi's surgical procedure for treatment of BPH. The study procedure will be performed in the operating room, under general anesthesia.~Subject will undergo a bilateral anastomosis of the internal spermatic vein to the inferior epigastric vein and ligation of the deferential vein via bilateral inguinal/subinguinal incision.~The investigators can use of a coupler with appropriate ring size (to be measured intra-operatively based on vessel size) to perform the vascular anastomosis and standard sutures for ligation. The coupler is an FDA approved commercial device. Alternatively, the anastomosis can also be performed using sutures. Incision closure will proceed per institution standard of care.
Study: NCT04637035

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Oncology Care at Home
Description: Intervention entailing remote monitoring of patients' symptoms, vital signs, and body weight with home-based care.
Study: NCT05657067

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotionally Focused Family Therapy (EFFT)
Description: The rationale behind EFFT is that mental health problems in children and adolescents often originate and/or are exacerbated by negative interaction patterns rooted in insecure attachment bonds within families. Therefore, the main treatment goal of EFFT is the development of secure attachment between parents and their children.
Study: NCT05514340

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline along with standard treatment
Description: Sovateltide is an endothelin-B receptor agonist. It has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in hypoxic-ischemic encephalopathy patients. In this arm normal saline along with standard treatment will be given for active comparison.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sovateltide along with standard treatment
Description: Sovateltide is an endothelin-B receptor agonist. It has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in hypoxic-ischemic encephalopathy patients. In this arm sovateltide along with standard treatment will be given for active comparison.
Study: NCT05757609

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tDCS combined with active physiotherapy
Description: anodal tDCS over prefrontal cortex combined with active physiotherapy

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham anodal tDCS combined with active physiotherapy
Description: Sham anodal tDCS over prefrontal cortex combined with active physiotherapy
Study: NCT05734716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: use of erythropoietin to stimulate red blood cell development prior to ascent to altitude

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron sucrose (Venofer)
Description: use of iron sucrose to stimulate red blood cell development prior to ascent to altitude

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Sodium Chloride
Description: sham treatment with sterile saline
Study: NCT06099964

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain Coping Information
Description: A 4-minute audio recording providing common pain coping techniques (e.g., ice, rest, medication, surgery).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Pain Management
Description: A 4-minute audio recording consisting of a 1-minute introduction to mindfulness followed by a 1-minute and 30-second mindful breathing practice and a 1-minute and 30-second mindfulness of pain practice.
Study: NCT06357741

Intervention type: DRUG
Intervention: Denosumab
Description: Desumumab, 60mg single injection

Intervention type: DRUG
Intervention: Denosumab
Description: Desumumab, 60mg single injection

Intervention type: DRUG
Intervention: Denosumab
Description: Desumumab, 60mg single injection

Intervention type: DRUG
Intervention: Denosumab
Description: Desumumab, 60mg single injection

Intervention type: DRUG
Intervention: Denosumab
Description: Desumumab, 60mg single injection

Intervention type: DRUG
Intervention: Denosumab
Description: Desumumab, 60mg single injection

Intervention type: DRUG
Intervention: Denosumab
Description: Desumumab, 60mg single injection

Intervention type: DRUG
Intervention: Denosumab
Description: Desumumab, 60mg single injection
Study: NCT06462495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]F-PSMA-N5
Description: Each subject receive a single intravenous injection of \[18F\]F-PSMA-N5, and undergo PET/CT imaging within the specificed time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]F-PSMA-1007
Description: Each subject receive a single intravenous injection of \[18F\]F-PSMA-1007, and undergo PET/CT imaging within the specificed time.
Study: NCT05003882

Intervention type: OTHER
Intervention: Commercially available, orally ingestible CBD product
Description: botanically-derived CBD extract product

Intervention type: OTHER
Intervention: Commercially available, orally ingestible CBD product
Description: botanically-derived CBD extract product

Intervention type: OTHER
Intervention: Commercially available, orally ingestible CBD product
Description: botanically-derived CBD extract product
Study: NCT06564818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYB003
Description: CYB003 is a synthetic psilocybin analog.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological Support
Description: Manualized psychological support performed by facilitators

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychological Support
Description: Manualized psychological support performed by facilitators

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05983159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirdametinib
Description: An investigational oral MEK inhibitor
Study: NCT06339112

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Playing with toy nebulizer
Description: The child who needs to take inhaler medication is taken to the observation room. Before starting the procedure, the toy nebulizer is introduced to the child. The toy nebulizer is shown to the child as an example and allowed to play, thus reducing the level of fear. Inhaler medication is given through a mask for 10 minutes. Vital signs (pulse) before and after the application. , blood pressure, SPo2, respiration), the Child Fear Scale will be evaluated by the researcher and the parent and recorded in the intervention follow-up form by the researcher.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cartoon
Description: Approximately 10 minutes for the child. Inhaler medication will be given with a mask that lasts. 2-3 minutes before starting drug treatment, the child will be allowed to watch cartoons according to his age group and will be encouraged to do so throughout the procedure.~Vital signs (pulse, blood pressure, SPo2, respiration) before and after the application, the Child Fear Scale will be evaluated by the researcher and the parent and recorded in the intervention follow-up form by the researcher.
Study: NCT05257720

Intervention type: DIAGNOSTIC_TEST
Intervention: GFAP, S100B
Description: It is planned to measure serum GFAP and S100 B protein levels by ELISA method.

Intervention type: DIAGNOSTIC_TEST
Intervention: GFAP, S100B
Description: It is planned to measure serum GFAP and S100 B protein levels by ELISA method.

Intervention type: DIAGNOSTIC_TEST
Intervention: GFAP, S100B
Description: It is planned to measure serum GFAP and S100 B protein levels by ELISA method.
Study: NCT05153226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg/kg (AIBW) i.v. d+3, d+4 post transplant

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ATG
Description: 10 mg/kg i.v. d-3, d-2, d-1 pre-transplant
Study: NCT06171750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANK-101
Description: IT administration of ANK-101 once every 3 weeks for up to 12 weeks (4 doses); if there is no disease progression, decrease in clinical performance status or unacceptable toxicity, participants may receive 4 additional doses of ANK-101.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANK-101
Description: IT administration of ANK-101 once every 3 weeks for up to 12 weeks (4 doses); if there is no disease progression, decrease in clinical performance status or unacceptable toxicity, participants may receive 4 additional doses of ANK-101.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANK-101
Description: IT administration of ANK-101 once every 3 weeks for up to 12 weeks (4 doses); if there is no disease progression, decrease in clinical performance status or unacceptable toxicity, participants may receive 4 additional doses of ANK-101.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Participants will receive four cycles of ANK-101 in combination with Cemiplimab. If there is no significant clinical deterioration as determined by the Investigator or unacceptable toxicity at Week 12, participants may receive an additional four cycles of the combination treatment. After stopping ANK-101 treatment, participants may stay on Cemiplimab monotherapy for an additional 24 weeks.